A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)

• Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)) (Biological): 1 dose of Tdcp vaccine (0.5ml) on day 0
• 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) (Biological): 1 dose of PPV23 vaccine (0.5ml) on day 0
• Tdcp (Biological): 1 dose of Tdcp vaccine (0.5ml) on day 0
• PPV23 (Biological): 1 dose of PPV23 vaccine (0.5ml) on day 0
• Tdcp (Biological): 1 dose of Tdcp vaccine (0.5ml) on day 0
• PPV23 (Biological): 1 dose of PPV23 vaccine (0.5ml) on day 0
• Tdcp (Biological): 1 dose of Tdcp vaccine (0.5ml) on day 0
• PPV23 (Biological): 1 dose of PPV23 vaccine (0.5ml) on day 0
• Tdcp (Biological): 1 dose of Tdcp vaccine (0.5ml) on day 0
• Diphtheria-tetanus-acellular pertussis vaccine (DTaP) (Biological): 1 dose of DTaP vaccine (0.5ml) on day 0

Primary outcomes

• Phase II: Incidence of adverse reactions [Within 0-30 days after vaccination]
• Phase III: Geometric mean concentration (GMC) of serum anti-PT, FHA, PRN, FIM 2&3, DT, TT antibodies [Pre-vaccination and 30 days post-vaccination]
• Phase III: Proportion of serum anti-DT and TT antibodies ≥ 0.1IU/ml [30 days after vaccination]
• Phase III: Incidence of adverse reactions [Within 0-30 days after vaccination]

Secondary outcomes

• Phase II: Incidence of adverse events/reactions [Within 30 minutes of vaccination]
• Phase II: Incidence of adverse events/reactions [0-7 days after vaccination]
• Phase II: Incidence of adverse events [0-30 days after vaccination]
• Phase II: Incidence of serious stadverse events [Within 6 months of vaccination]
• Phase III: Positive rate of serum anti-Pertussis Toxoid (PT), Filamentous hemagglutmin (FHA), Pertactin (PRN), FIM 2&3, Diphtheria Toxoid (DT), Tetanus Toxoid (TT) antibodies [30 days after vaccination]
• Phase III: Positive transfer rate of serum anti-PT, FHA, PRN, FIM 2&3, DT, TT antibodies [30 days after vaccination]
• Phase III: Geometric Mean Increase (GMI) of serum anti-PT, FHA, PRN, FIM 2&3, DT, TT antibodies [30 days after vaccination]
• Phase III: Incidence of adverse events/reactions [Within 30 minutes of vaccination]
• Phase III: Incidence of adverse events/reactions [0-7 days after vaccination]
• Phase III: Incidence of adverse events [0-30 days after vaccination]
• Phase III: Incidence of SAEs in subjects aged 7 years and older [Within 6 months of vaccination]
• Phase III: Incidence of SAEs in subjects aged 6 years [Within 12 months of vaccination]

Other outcomes

• Seropositivity rates of antibodies against PT, FHA, PRN, FIM2&3, DT, and TT in the immunopersistence subgroup [12 months, 3 years, and 5 years post-vaccination]
• Geometric mean concentrations (GMC) of antibodies against PT, FHA, PRN, FIM2&3, DT, and TT in the immunopersistence subgroup [12 months, 3 years, and 5 years post-vaccination]
• The proportion of serum anti-PRN antibodies ≥ 5 IU/mL [30 days, 12 months, 3 years, and 5 years post-vaccination]
• The proportion of serum anti-FIM2&3 antibodies ≥ 5 EU/mL [30 days, 12 months, 3 years, and 5 years post-vaccination]
• The proportion of serum anti-PRN antibodies ≥ 10 IU/mL [30 days, 12 months, 3 years, and 5 years post-vaccination]
• The proportion of serum anti-FIM2&3 antibodies ≥ 10 EU/mL [30 days, 12 months, 3 years, and 5 years post-vaccination]
• The proportion of serum anti-PRN antibodies ≥ 20 IU/mL [12 months, 3 years, and 5 years post-vaccination]
• The proportion of serum anti-FIM2 & 3 antibodies ≥ 20 EU/mL [12 months, 3 years, and 5 years post-vaccination]
• The proportion of serum anti-DT antibodies ≥ 0.1 IU/mL [12 months, 3 years, and 5 years post-vaccination]
• The proportion of serum anti-TT antibodies ≥ 0.1 IU/mL [12 months, 3 years, and 5 years post-vaccination]

Sex: All, ages: 6 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Phase II : People ≥ 7 years old
* Phase II : Willing to provide identification documents
* Phase II : Volunteers must obtain informed consent from the volunteers themselves and/or their guardians/ or delegates, sign the informed consent form and be willing to comply with the requirements of the clinical trial protocol, and be able to complete the full study follow-up
* Phase II : Volunteers aged 7\~11 years have completed 4 doses of vaccine containing DPT
* Phase II : ≥12 years old volunteers need to have not received any component vaccine containing DPT within 5 years
* Phase III : People ≥6 years old
* Phase III : Willing to provide identification documents
* Phase III : Volunteers must obtain informed consent from themselves and/or their guardians/ or delegates, sign the informed consent form and be willing to comply with the requirements of the clinical trial protocol, and be able to complete the full study follow-up
* Phase III : Volunteers aged 6\~11 years old have completed 4 doses of DPT-containing vaccine in the past
* Phase III : Volunteers aged ≥12 years should not have received any vaccine containing any component of DPT within 5 years

Exclusion Criteria:

* Those who have fever before vaccination, with axillary temperature >37.0℃;
* Females with a positive urine pregnancy test or breastfeeding volunteers, volunteers or their partners who have a pregnancy plan within 6 months;
* Suffering from hypertension (systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg) that cannot be controlled by medication (applicable to people aged 18 years and above);
* Those who have already suffered from one of the diphtheria or tetanus diseases, those who have suffered from whooping cough in the last 3 years; or those who have had persistent cough for 14 days or more in the last 6 months;
* Those who have received vaccine containing pneumococcal polysaccharide/conjugate component within 5 years (applicable to those aged 7 years and above);
* Individuals who have had household contact with an individual with a confirmed diagnosis of pertussis, diphtheria, or tetanus disease in the past 30 days;
* Individuals who are allergic to the components of the test vaccine (e.g., aluminum adjuvant, sodium dihydrogen phosphate, sodium chloride, etc.) or who have developed an allergy to the same type of vaccine previously; individuals with a previous history of severe allergy, e.g., recurrent generalized urticaria, anaphylactic shock, respiratory distress, angioneurotic edema, or a history of asthma;
* Those with encephalopathy, uncontrolled epilepsy and other progressive neurological disorders (e.g., transverse myelitis, Guillain-Barre syndrome, demyelinating diseases)
* Persons with primary and secondary impaired immune function, receiving immunosuppressive therapy
* Doctor-diagnosed coagulation abnormalities (e.g. coagulation factor deficiencies, coagulopathies, platelet abnormalities) or significant bruising or coagulation disorders
* Currently suffering from severe chronic diseases, acute exacerbation of chronic diseases, acute infectious diseases;
* Have received another investigational drug or vaccine within 1 month prior to receiving the experimental vaccine, or have plans to participate or are participating in a clinical study of any other drug;
* Have received an injectable live attenuated vaccine within 14 days prior to receiving the experimental vaccine, or any other vaccine within 7 days prior to receiving the experimental vaccine;
* In the judgment of the investigator, the volunteer has any other factors that make him/her unsuitable for participation in the clinical trial.

• Hanqing He, Principal investigator, Ethical Review Committee for Clinical Trials of Zhejiang Center for Disease Control and Prevention